Earle Burgess
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Earle Burgess
Mar 14, 2024, 09:34 |
Drugs
Earle Burgess: Analysis of the just published EV-302 study
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared a post by LinkedIn: "Is…
Jan 31, 2024, 17:49 |
Insight
Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available
Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn: "Enfortumab vedotin is…
Jan 30, 2024, 14:58 |
Insight
Earle Burgess: How should we incorporate the results of the Embark trial
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer, posted on LinkedIn: "How should we…
Jan 25, 2024, 13:22 |
Insight
Earle Burgess: Bacterial species in stool predict whether someone will respond to cancer therapy
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer, posted on LinkedIn: "Bacterial species…
Dec 13, 2023, 17:53 |
Blog
Earle Burgess: Why don’t all advanced prostate cancer patients with pathogenic HRR gene mutations respond to parp inhibitors?
Earle Burgess, Chief of Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, shared a…
Dec 8, 2023, 17:46 |
Drugs
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Earle Burgess, Chief of the Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, shared…
Nov 6, 2023, 00:56 |
Blog
Earle Burgess: We finally have evidence that a triplicate regimen in bladder cancer is better than chemo alone
Earle Burgess, Chief, Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, made the following…
Aug 25, 2023, 18:22 |
Insight
Earle Burgess: Which newly diagnosed metastatic castrate-sensitive prostate cancer patients need to add docetaxel chemotherapy to an ADT + ARPI doublet?
Quoting Earle Burgess, Genitourinary Medical Oncologist and Clinical Researcher at Atrium Health, Levine Cancer Institute,…
All:
8
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube